OncoMatch/Clinical Trials/NCT05803018
A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies
Is NCT05803018 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies BL-B01D1 for gynecological malignant tumor.
Treatment: BL-B01D1 — A phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics and efficacy of BL-B01D1 for injection in patients with multiple solid tumors, including recurrent or metastatic gynecological malignancies.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Ovarian Cancer
Endometrial Cancer
Cervical Cancer
Tumor Agnostic
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: standard treatment
failed standard treatment, intolerance to standard treatment, or no current standard treatment available
Cannot have received: chemotherapy
Received chemotherapy...within 4 weeks or 5 half-lives prior to the first dose (6 weeks for mitomycin and nitrosoureas; oral fluorouracil drugs, etc.)
Cannot have received: biological therapy
Received...biological therapy...within 4 weeks or 5 half-lives prior to the first dose
Cannot have received: immunotherapy
Received...immunotherapy...within 4 weeks or 5 half-lives prior to the first dose
Cannot have received: other antitumor treatments
Received...other antitumor treatments within 4 weeks or 5 half-lives prior to the first dose
Cannot have received: anthracycline
Cumulative anthracycline dose >360 mg/m² in prior (neo)adjuvant anthracycline therapy
Lab requirements
Blood counts
Toxicity from prior anti-tumor therapy has recovered to ≤ Grade 1 as defined by NCI-CTCAE v5.0; Organ function levels must meet the requirements without transfusion, albumin, colony-stimulating factors, any cell growth factors, and/or platelet-raising drugs within 14 days before the first dose of the study drug; Coagulation function: INR ≤1.5, and APTT ≤1.5 × ULN; Urine protein ≤2+ or ≤1000 mg/24h
Kidney function
Liver function
Cardiac function
No severe cardiac dysfunction, with left ventricular ejection fraction (LVEF) ≥50%
No severe cardiac dysfunction, with left ventricular ejection fraction (LVEF) ≥50%; Organ function levels must meet the requirements...; Coagulation function: INR ≤1.5, and APTT ≤1.5 × ULN; Urine protein ≤2+ or ≤1000 mg/24h
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05803018 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior chemotherapy, biological therapy, immunotherapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages